Eurand's pancreatic insufficiency treatment Zenpep wins US approval
This article was originally published in Scrip
Executive Summary
Eurand's Zenpep (pancrelipase delayed-release, formerly EUR-1008) has become the second pancreatic enzyme product (PEP) approved under a US FDA initiative aimed at getting unapproved formulations off the market. Zenpep is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.